Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Smith_kb
INDICATIONS [/za_1075.html#1] [/za_1075.html#1] [/za_1075.html#1] CONTRA-INDICATIONS [/za_1075.html#1] [/za_1075.html#1] DOSAGE [/za_1075.html#1] [/za_1075.html#1] SIDE-EFFECTS [/za_1075.html#1] [/za_1075.html#1] [/za_1075.html#1] PREGNANCY [/za_1075.html#1] [/za_1075.html#1] OVERDOSE [/za_1075.html#1] IDENTIFICATION [/za_1075.html#1] [/za_1075.html#1] PATIENT INFORMATION FLOXAPEN 250 (CAPSULES) FLOXAPEN S (SYRUP) SCHEDULING STATUS: S4 PROPRIETARY NAMES (and dosage form): FLOXAPEN 250 (CAPSULES) FLOXAPEN S (SYRUP) COMPOSITION: FLOXAPEN 250 : Gelatin capsules containing FLUCLOXACILLIN sodium equivalent to 250 mg flucloxacillin. FLOXAPEN S: Powder for preparing citrus-flavoured syrup. When dispensed as directed, each 5 mL of the syrup contains flucloxacillin sodium equivalent to 125 mg flucloxacillin. The powder contains 0,13% m/m sodium benzoate B.P. as a preservative. PHARMACOLOGICAL CLASSIFICATION: A.20.1.2 Penicillins PHARMACOLOGICAL ACTION: FLOXAPEN is a semi-synthetic penicillin derived from 6-amino-penicillanic acid and is the latest of the series of penicillinase stable penicillins. (A) BACTERIOLOGY FLOXAPEN exhibits bactericidal activity against all Gram-positive organisms (with the exception of Strep. faecalis) e.g. Haemolytic streptococci, staphylococci, streptococcus pneumoniae and N. gonorrhoeae. FLOXAPEN’S anti-staphylococcal activity is not affected by penicillinase and as FLOXAPEN is active against virtually all strains ofStaph. aureus (methicillin-resistant strains being the only exception), it is particularly indicated in the treatment of staphylococcal infections. The MIC’s of benzylpenicillin against staphylococci are lower than those of flucloxacillin except in the case of the penicillinase-producing staphylococci. (B) ABSORPTION FLOXAPEN is ext Read the complete document